---
abstract: ''
authors:
- Rebitch, Catherine B
category: Clinical Review
clinical_significance: High
cme_credits: 0.0
doi: ''
evidence_level: ''
external_resources:
- title: PubMed Entry
  type: reference
  url: https://pubmed.ncbi.nlm.nih.gov/37440749/
file_path: 2023/07/tirzepatide-mounjaro-for-the-treatment-of-type-2-diabetes-me.md
issue: '1'
keywords:
- Gastric Inhibitory Polypeptide
- Diabetes Mellitus, Type 2
- Humans
- Diabetes
- Glucagon-Like Peptide-1 Receptor
- Tirzepatide
- Hypoglycemic Agents
last_updated: '2025-08-09'
mesh_terms:
- Humans
- Diabetes Mellitus, Type 2
- Gastric Inhibitory Polypeptide
- Hypoglycemic Agents
- Glucagon-Like Peptide-1 Receptor
- Tirzepatide
original_format: PubMed
pages: 93-94
patient_population: Adults
peer_reviewed: true
pmid: '37440749'
processed_date: '2025-08-09'
publication_date: '2023-07-01'
pubmed_enriched: true
pubmed_enriched_date: '2025-08-09'
reading_time_minutes: 1
source: American family physician
specialties:
- Family Medicine
status: processed
tags:
- clinical-review
- family-practice
- clinical-medicine
- pubmed-enhanced
title: Tirzepatide (Mounjaro) for the Treatment of Type 2 Diabetes Mellitus.
topics:
- Diabetes Mellitus
- Endocrinology
- Family Medicine
- Metabolic Disorders
volume: '108'
publication_types: &id001
- Journal Article
pubmed_content_enriched: true
pubmed_full_data:
  pmid: '37440749'
  title: Tirzepatide (Mounjaro) for the Treatment of Type 2 Diabetes Mellitus.
  authors:
  - last_name: Rebitch
    fore_name: Catherine B
    initials: CB
    affiliation: University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania.
  journal_info:
    title: American family physician
    iso_abbreviation: Am Fam Physician
    volume: '108'
    issue: '1'
  publication_info:
    year: '2023'
    month: '07'
    full_date: '2023-07-01'
  article_ids: {}
  mesh_terms:
  - descriptor: Humans
    major_topic: false
  - descriptor: Diabetes Mellitus, Type 2
    major_topic: true
    qualifiers:
    - qualifier: drug therapy
      major_topic: false
  - descriptor: Gastric Inhibitory Polypeptide
    major_topic: false
  - descriptor: Hypoglycemic Agents
    major_topic: false
    qualifiers:
    - qualifier: therapeutic use
      major_topic: false
  - descriptor: Glucagon-Like Peptide-1 Receptor
    major_topic: false
  - descriptor: Tirzepatide
    major_topic: false
  publication_types: *id001
related_articles:
- pmid: '37440749'
  title: Tirzepatide (Mounjaro) for the Treatment of Type 2 Diabetes Mellitus.
  authors:
  - name: Rebitch CB
    authtype: Author
    clusterid: ''
  source: Am Fam Physician
  pubdate: 2023 Jul
- pmid: '36200219'
  title: 'Tirzepatide: A New Generation Therapeutic for Diabetes Type 2.'
  authors:
  - name: Al-Horani RA
    authtype: Author
    clusterid: ''
  - name: Chedid M
    authtype: Author
    clusterid: ''
  source: Endocr Metab Immune Disord Drug Targets
  pubdate: '2023'
- pmid: '37218275'
  title: Tirzepatide (Mounjaro) - a novel Pharmacotherapeutic Agent for Obesity.
  authors:
  - name: Tayyaba
    authtype: CollectiveName
    clusterid: ''
  - name: Siddiqui T
    authtype: Author
    clusterid: ''
  - name: Doultani PR
    authtype: Author
    clusterid: ''
  source: J Pak Med Assoc
  pubdate: 2023 May
- pmid: '38133594'
  title: Tirzepatide (Zepbound) for chronic weight management.
  authors: []
  source: Med Lett Drugs Ther
  pubdate: 2023 Dec 25
- pmid: '35802842'
  title: Tirzepatide (Mounjaro) for type 2 diabetes.
  authors: []
  source: Med Lett Drugs Ther
  pubdate: 2022 Jul 11
---

# Tirzepatide (Mounjaro) for the Treatment of Type 2 Diabetes Mellitus.

**Authors:** Rebitch, Catherine B

**Published in:** American family physician | Vol. 108, No. 1 | 2023-07-01

**Links:** [PubMed Entry](https://pubmed.ncbi.nlm.nih.gov/37440749/)

## Clinical Information

**Population:** Adults | **Clinical Significance:** High

## Topics & Specialties

**Specialties:** Family Medicine

**Topics:** Diabetes Mellitus, Endocrinology, Family Medicine, Metabolic Disorders

## MeSH Terms

Humans, Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide, Hypoglycemic Agents, Glucagon-Like Peptide-1 Receptor, Tirzepatide

## Article Content

# Tirzepatide (Mounjaro) for the Treatment of Type 2 Diabetes Mellitus.

**Authors:** Rebitch, Catherine B

**Published in:** American family physician | Vol. 108, No. 1 | 2023-07-01

**Links:** [PubMed](https://pubmed.ncbi.nlm.nih.gov/37440749/)

## Clinical Information

**Population:** Adults | **Clinical Significance:** High

## Topics & Specialties

**Specialties:** Family Medicine

**Topics:** Diabetes Mellitus, Endocrinology, Family Medicine, Metabolic Disorders

## MeSH Terms

Humans, Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide, Hypoglycemic Agents, Glucagon-Like Peptide-1 Receptor, Tirzepatide

## Article Content

*Full article content to be extracted and formatted from source material.*

## Additional Resources

- [PubMed Entry](https://pubmed.ncbi.nlm.nih.gov/37440749/) (reference)

---

*Processed: 2025-07-30* | *PubMed Enhanced: 2025-07-30*

## Additional Resources

- [PubMed Entry](https://pubmed.ncbi.nlm.nih.gov/37440749/) (reference)

---

*Processed: 2025-08-09* | *PubMed Enhanced: 2025-07-30*
